SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wright V. Seronegative polyarthritis: a unified concept. Arthritis Rheum 1978; 21: 61933.
  • 2
    Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 1992; 18: 187202.
  • 3
    Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988; 27 Suppl 2: 95105.
  • 4
    Mielants H, Veys EM, de Vos M, Cuvelier C, Goemaere S, de Clercq L et al. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995; 22: 226672.
  • 5
    De Vos M, Mielants H, Cuvelier C, Elewaut D, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696703.
  • 6
    Mielants H, Veys EM, Cuvelier C, de Vos M, Goemaere S, de Clercq L et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22: 22738.
  • 7
    Dick AP, Grayson MJ, Carpenter RC, Petrie A. Controlled trial of sulfasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 43742.
  • 8
    Van Hees PA, van Lier HJ, van Elteren PH, Driessen M, van Hogezand RA, Ten Velde GP et al. Effect of sulfasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981; 22: 4049.
  • 9
    Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 61827.
  • 10
    Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42:23259.
  • 11
    Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797809.
  • 12
    Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324: 27784.
  • 13
    Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 58993.
  • 14
    Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 144353.
  • 15
    Van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 12935.
  • 16
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 102935.
  • 17
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 18
    Van den Bosch F, Kruithof E, de Vos M, de Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on the articular symptoms. Lancet 2000; 356: 18212.
  • 19
    Antoni C, Dechant C, Lorenz H, Olgivie A, Kalden-Nemeth D, Kalden J et al. Successful treatment of severe psoriatic arthritis with infliximab [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S371.
  • 20
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 38590.
  • 21
    Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499505.
  • 22
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 110510.
  • 23
    Maini RN, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al, ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 24
    Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 42833.
  • 25
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 26
    Baeten D, van den Bosch F, Elewaut D, Stuer A, Veys EM, de Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999; 18: 43441.
  • 27
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al. European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 121827.
  • 28
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 29
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21: 228691.
  • 30
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994; 21: 22815.
  • 31
    Dougados M, Gueguen A, Nakache JP, Nguyen M, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988; 15: 3027.
  • 32
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol 1994; 21: 16948.
  • 33
    Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 23844.
  • 34
    Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 238390.
  • 35
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 47886.
  • 36
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 37
    Baeten D, van Damme N, van den Bosch F, Kruithof E, de Vos M, Mielants H et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001; 60: 7505.
  • 38
    Baeten D, Kruithof E, van den Bosch F, Demetter P, van Damme N, Cuvelier C et al. Immunomodulatory effects of anti–tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 18695.